Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Director Ernest Mario purchased 120,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 23rd. The shares were acquired at an average price of $0.41 per share, for a total transaction of $49,200.00. Following the completion of the transaction, the director now owns 630,724 shares in the company, valued at $258,596.84. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Ernest Mario also recently made the following trade(s):

  • On Tuesday, September 13th, Ernest Mario purchased 100,000 shares of Tonix Pharmaceuticals Holding Corp. stock. The shares were acquired at an average price of $0.79 per share, for a total transaction of $79,000.00.

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) opened at 0.3812 on Thursday. Tonix Pharmaceuticals Holding Corp. has a 12 month low of $0.35 and a 12 month high of $7.95. The firm has a 50-day moving average price of $0.50 and a 200-day moving average price of $1.56. The company’s market capitalization is $14.94 million.

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) last issued its quarterly earnings data on Thursday, November 10th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.05. On average, equities analysts anticipate that Tonix Pharmaceuticals Holding Corp. will post ($1.59) earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)

TRADEMARK VIOLATION NOTICE: This report was first published by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another publication, it was stolen and republished in violation of U.S. and international copyright & trademark law. The original version of this report can be viewed at http://www.dailypolitical.com/2016/12/01/insider-buying-tonix-pharmaceuticals-holding-corp-tnxp-director-purchases-49200-00-in-stock.html.

TNXP has been the topic of a number of research analyst reports. Cantor Fitzgerald restated a “buy” rating and set a $5.00 price target on shares of Tonix Pharmaceuticals Holding Corp. in a research report on Wednesday, August 24th. Roth Capital lowered Tonix Pharmaceuticals Holding Corp. from a “buy” rating to a “neutral” rating in a research report on Wednesday, September 7th. Finally, Oppenheimer Holdings Inc. lowered Tonix Pharmaceuticals Holding Corp. from an “outperform” rating to a “market perform” rating in a research report on Wednesday, September 7th.

Large investors have recently modified their holdings of the stock. Sabby Management LLC boosted its stake in shares of Tonix Pharmaceuticals Holding Corp. by 52.0% in the second quarter. Sabby Management LLC now owns 585,914 shares of the company’s stock valued at $1,166,000 after buying an additional 200,518 shares during the period. Opaleye Management Inc. bought a new stake in shares of Tonix Pharmaceuticals Holding Corp. during the second quarter valued at about $1,592,000. Franklin Resources Inc. boosted its stake in shares of Tonix Pharmaceuticals Holding Corp. by 279.4% in the second quarter. Franklin Resources Inc. now owns 1,610,045 shares of the company’s stock valued at $3,204,000 after buying an additional 1,185,664 shares during the period. Vanguard Group Inc. boosted its stake in shares of Tonix Pharmaceuticals Holding Corp. by 1.5% in the second quarter. Vanguard Group Inc. now owns 707,065 shares of the company’s stock valued at $1,407,000 after buying an additional 10,531 shares during the period. Finally, Jacobs Levy Equity Management Inc. bought a new stake in shares of Tonix Pharmaceuticals Holding Corp. during the first quarter valued at about $290,000. Institutional investors and hedge funds own 10.25% of the company’s stock.

5 Day Chart for NASDAQ:TNXP

Receive News & Ratings for Tonix Pharmaceuticals Holding Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals Holding Corp. and related companies with MarketBeat.com's FREE daily email newsletter.